GlassScriptPhysician profile
Todd A Robinson
NPI 1497791792
$1,663.64
in general payments reported to CMS, 2019-2025
36 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $83.66 · 2021: $333 · 2022: $219 · 2023: $148 · 2024: $507 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $807.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $372.01 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $151.55 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Myovant Sciences INC. | $104.07 | 2021-2022 | |
| Hologic Sales and Service, LLC | $93.29 | 2022-2024 | Acessa Provu System, Thinprep 2000 Processor, Omni Hysteroscope |
| Lilly USA, LLC | $74.22 | 2024 | Zepbound, Mounjaro |
| Shield Therapeutics INC | $70.12 | 2022-2024 | Accrufer |
| Boston Scientific Corporation | $69.27 | 2024-2025 | General - Pain Management |
| Abbvie INC. | $53.74 | 2019-2022 | |
| Pfizer INC. | $51.60 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $43.28 | 2024-2025 | |
| Amarin Pharma, INC. | $42.85 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $42.51 | 2023 | Quviviq |
| Exeltis, USA INC. | $39.21 | 2022-2024 | Slynd |
| Amag Pharmaceuticals, INC. | $35.77 | 2019 | |
| Dexcom, INC. | $34.40 | 2024 | Dexcom G6 Transmitter |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $30.98 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $28.28 | 2019-2020 | |
| Organon LLC | $25.26 | 2025 | Nexplanon |
| Allergan, INC. | $24.42 | 2019 | |
| Evofem Biosciences, INC. | $23.55 | 2020 | |
| Scynexis, INC. | $20.81 | 2022 | |
| Genentech USA, INC. | $19.26 | 2019 | |
| Abbott Laboratories | $18.48 | 2025 | Freestyle Libre 3 |
| Aspira Women'S Health INC | $18.39 | 2022 | |
| Jazz Pharmaceuticals INC. | $18.14 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.08 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.53 | 2020 | |
| Sumitomo Pharma America, INC. | $15.67 | 2024 | Myfembree |
| Takeda Pharmaceuticals U.S.A., INC. | $14.43 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.43 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.31 | 2021 | |
| Amgen INC. | $13.26 | 2020 | |
| Clarus Therapeutics INC. | $12.87 | 2021 | |
| Therapeuticsmd, INC. | $12.64 | 2022 | |
| Bausch Health US, LLC | $12.51 | 2021 | |
| Minerva Surgical, INC | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.